Medroxyprogesterone vs Raloxifene: side-by-side comparison
Medroxyprogesterone (Progestin) and Raloxifene (Selective estrogen receptor modulator (SERM)) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Medroxyprogesterone | Raloxifene |
|---|---|---|
| Therapeutic class | Progestin | Selective estrogen receptor modulator (SERM) |
| CAS | 520-85-4 | 84449-90-1 |
| ATC | G03DA02 | G03XC01 |
| Molecular weight | 344.49 g/mol | 473.59 g/mol |
| Brands with this active ingredient | 1 | 1 |
What they share
Medroxyprogesterone and Raloxifene share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Medroxyprogesterone acts by a different mechanism than Raloxifene, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Medroxyprogesterone: MPA binds progesterone receptors and produces strong progestational effects: thickening cervical mucus, inhibiting ovulation, thinning the endometrium and reducing hot flashes. Raloxifene: Raloxifene binds estrogen receptors and produces tissue-selective effects: estrogen-agonist activity in bone (preserving bone mineral density) and on lipid metabolism (lowering LDL cholesterol), while exhibiting estrogen…
Indications compared
Medroxyprogesterone: MPA is approved for amenorrhoea, abnormal uterine bleeding due to hormonal imbalance, prevention of endometrial hyperplasia in postmenopausal women receiving estrogen, and prevention of pregnancy (depot formulation). Raloxifene: Raloxifene is approved for prevention and treatment of postmenopausal osteoporosis, and for reduction of invasive breast cancer risk in postmenopausal women at increased risk.
Safety profile
Medroxyprogesterone: Common adverse effects of oral MPA include irregular bleeding, breast tenderness, mood changes, fluid retention and weight gain. Raloxifene: Common adverse effects include hot flashes (paradoxically common because raloxifene is a partial estrogen agonist/antagonist), leg cramps and peripheral oedema.
Frequently asked questions
Is Medroxyprogesterone better than Raloxifene? ▾
Medroxyprogesterone and Raloxifene are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Medroxyprogesterone and Raloxifene be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Medroxyprogesterone
Products with Raloxifene
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.